Exhibit 12.02


                                  CERTIFICATION




I, Eric Merrigan, Chief Financial Officer, certify that:

1. I have reviewed this annual report on Form 20-F of ChemGenex Pharmaceuticals
Limited;

2. Based on my knowledge, this report does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the company as of,
and for, the periods presented in this report;

4. The company's other certifying officer and I are responsible for establishing
and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) for the company and have:

           (a) Designed such disclosure controls and procedures, or caused such
           disclosure controls and procedures to be designed under our
           supervision, to ensure that material information relating to the
           company, including its consolidated subsidiaries, is made known to us
           by others within those entities, particularly during the period in
           which this report is being prepared;

           (b) [Paragraph omitted pursuant to SEC Release Nos. 33-8238 and
           34-47986]

           (c) Evaluated the effectiveness of the company's disclosure controls
           and procedures and presented in this report our conclusions about the
           effectiveness of the disclosure controls and procedures, as of the
           end of the period covered by this report based on such evaluation;
           and

           (d) Disclosed in this report any change in the company's internal
           control over financial reporting that occurred during the period
           covered by the annual report that has materially affected, or is
           reasonably likely to materially affect the company's internal control
           over financial reporting; and

5. The company's other certifying officer and I have disclosed, based on our
most recent evaluation of internal control over financial reporting, to the
company's auditors and the audit committee of the company's board of directors
(or persons performing the equivalent functions):

           (a) All significant deficiencies and material weaknesses in the
           design or operation of internal control over financial reporting
           which are reasonably likely to adversely affect the company's ability
           to record, process, summarize and report financial information; and

           (b) Any fraud, whether or not material, that involves management or
           other employees who have a significant role in the company's internal
           control over financial reporting.

                                                     Date: December 16, 2005

                                                     /s/Eric Merrigan
                                                     ------------------------
                                                     Eric Merrigan
                                                     Chief Financial Officer

     A signed original of this written statement required by Section 302 has
   been provided to ChemGenex Pharmaceuticals Limited and will be retained by
             ChemGenex Pharmaceuticals Limited and furnished to the
          Securities and Exchange Commission or its staff upon request.